Announcements
- Applied Therapeutics Added to Russell 3000® Index
- Applied Therapeutics Reports First Quarter 2024 Financial Results
- Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
- Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
- Applied Therapeutics Announces $100 Million Private Placement
- Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
More ▼
Key statistics
As of last trade Applied Therapeutics Inc (2UV:DUS) traded at 4.01, 8.92% above its 52-week low of 3.68, set on May 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.01 |
---|---|
High | 4.01 |
Low | 4.01 |
Bid | 4.01 |
Offer | 4.10 |
Previous close | 4.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 114.27m |
Free float | 107.47m |
P/E (TTM) | -- |
Market cap | 500.49m USD |
EPS (TTM) | -1.91 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 11:30 BST.
More ▼